The global Targeted Radionuclide Therapy market size was valued at USD 1073.2 million in 2022 and is forecast to a readjusted size of USD 3154.4 million by 2029 with a CAGR of 16.7% during review period.
Therapeutic Radioligands is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.
The key drivers of the radioimmunotherapy market is its potential to deliver highly targeted and precise treatment to cancer cells, sparing healthy tissues and reducing side effects compared to traditional radiation therapies. The ability of RIT to offer personalized treatment options based on specific cancer biomarkers further enhances its appeal in the field of precision medicine. However, the radioimmunotherapy market also faces challenges. One major challenge is the high cost associated with the development and production of radiopharmaceuticals, limiting access for some patients and healthcare systems. Additionally, navigating complex regulatory pathways for approval and reimbursement of RIT products can be time-consuming and resource-intensive for pharmaceutical companies. Furthermore, there may be limited awareness and acceptance of RIT among healthcare professionals and patients, leading to slower adoption rates and market penetration. Addressing these challenges requires continued research and investment in RIT technologies to improve efficacy and cost-effectiveness. Collaborations between pharmaceutical companies, research institutions, and healthcare organizations can facilitate knowledge-sharing and streamline the regulatory process.
Report includes an overview of the development of the Targeted Radionuclide Therapy industry chain, the market status of Solid Tumor (Beta-emitting, Targeted Alpha Therapy), Non Hodgkin Lymphoma (Beta-emitting, Targeted Alpha Therapy), and key enterprises in developed and developing market, and analyzed the cutting-edge technology, patent, hot applications and market trends of Targeted Radionuclide Therapy.
Regionally, the report analyzes the Targeted Radionuclide Therapy markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Targeted Radionuclide Therapy market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Targeted Radionuclide Therapy market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Targeted Radionuclide Therapy industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Beta-emitting, Targeted Alpha Therapy).
Industry Analysis: Report analyze the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Targeted Radionuclide Therapy market.
Regional Analysis: The report involves examining the Targeted Radionuclide Therapy market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behavior to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Targeted Radionuclide Therapy market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Targeted Radionuclide Therapy:
Company Analysis: Report covers individual Targeted Radionuclide Therapy players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behavior, preferences, and attitudes towards Targeted Radionuclide Therapy This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Solid Tumor, Non Hodgkin Lymphoma).
Technology Analysis: Report covers specific technologies relevant to Targeted Radionuclide Therapy. It assesses the current state, advancements, and potential future developments in Targeted Radionuclide Therapy areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Targeted Radionuclide Therapy market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Bayer
Novartis
Lantheus
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Curium Pharmaceuticals
Gilead Sciences
Clarity Pharmaceuticals
Curasight
Nordic Nanovector
Philogen
RadioMedix
Telix Pharmaceuticals
Orano Med
Actinium Pharmaceuticals
Y-mAbs Therapeutics
Fusion Pharmaceuticals
Beta-emitting
Targeted Alpha Therapy
Solid Tumor
Non Hodgkin Lymphoma
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Targeted Radionuclide Therapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Targeted Radionuclide Therapy, with revenue, gross margin and global market share of Targeted Radionuclide Therapy from 2018 to 2023.
Chapter 3, the Targeted Radionuclide Therapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Targeted Radionuclide Therapy market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Targeted Radionuclide Therapy.
Chapter 13, to describe Targeted Radionuclide Therapy research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Targeted Radionuclide Therapy
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Targeted Radionuclide Therapy by Type
1.3.1 Overview: Global Targeted Radionuclide Therapy Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Targeted Radionuclide Therapy Consumption Value Market Share by Type in 2022
1.3.3 Beta-emitting
1.3.4 Targeted Alpha Therapy
1.4 Global Targeted Radionuclide Therapy Market by Application
1.4.1 Overview: Global Targeted Radionuclide Therapy Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Solid Tumor
1.4.3 Non Hodgkin Lymphoma
1.5 Global Targeted Radionuclide Therapy Market Size & Forecast
1.6 Global Targeted Radionuclide Therapy Market Size and Forecast by Region
1.6.1 Global Targeted Radionuclide Therapy Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Targeted Radionuclide Therapy Market Size by Region, (2018-2029)
1.6.3 North America Targeted Radionuclide Therapy Market Size and Prospect (2018-2029)
1.6.4 Europe Targeted Radionuclide Therapy Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Targeted Radionuclide Therapy Market Size and Prospect (2018-2029)
1.6.6 South America Targeted Radionuclide Therapy Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Targeted Radionuclide Therapy Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 Bayer
2.1.1 Bayer Details
2.1.2 Bayer Major Business
2.1.3 Bayer Targeted Radionuclide Therapy Product and Solutions
2.1.4 Bayer Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Bayer Recent Developments and Future Plans
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis Targeted Radionuclide Therapy Product and Solutions
2.2.4 Novartis Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Novartis Recent Developments and Future Plans
2.3 Lantheus
2.3.1 Lantheus Details
2.3.2 Lantheus Major Business
2.3.3 Lantheus Targeted Radionuclide Therapy Product and Solutions
2.3.4 Lantheus Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Lantheus Recent Developments and Future Plans
2.4 Aurobindo Pharma
2.4.1 Aurobindo Pharma Details
2.4.2 Aurobindo Pharma Major Business
2.4.3 Aurobindo Pharma Targeted Radionuclide Therapy Product and Solutions
2.4.4 Aurobindo Pharma Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Aurobindo Pharma Recent Developments and Future Plans
2.5 Mundipharma
2.5.1 Mundipharma Details
2.5.2 Mundipharma Major Business
2.5.3 Mundipharma Targeted Radionuclide Therapy Product and Solutions
2.5.4 Mundipharma Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Mundipharma Recent Developments and Future Plans
2.6 China Isotope & Radiation
2.6.1 China Isotope & Radiation Details
2.6.2 China Isotope & Radiation Major Business
2.6.3 China Isotope & Radiation Targeted Radionuclide Therapy Product and Solutions
2.6.4 China Isotope & Radiation Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 China Isotope & Radiation Recent Developments and Future Plans
2.7 Curium Pharmaceuticals
2.7.1 Curium Pharmaceuticals Details
2.7.2 Curium Pharmaceuticals Major Business
2.7.3 Curium Pharmaceuticals Targeted Radionuclide Therapy Product and Solutions
2.7.4 Curium Pharmaceuticals Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Curium Pharmaceuticals Recent Developments and Future Plans
2.8 Gilead Sciences
2.8.1 Gilead Sciences Details
2.8.2 Gilead Sciences Major Business
2.8.3 Gilead Sciences Targeted Radionuclide Therapy Product and Solutions
2.8.4 Gilead Sciences Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Gilead Sciences Recent Developments and Future Plans
2.9 Clarity Pharmaceuticals
2.9.1 Clarity Pharmaceuticals Details
2.9.2 Clarity Pharmaceuticals Major Business
2.9.3 Clarity Pharmaceuticals Targeted Radionuclide Therapy Product and Solutions
2.9.4 Clarity Pharmaceuticals Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Clarity Pharmaceuticals Recent Developments and Future Plans
2.10 Curasight
2.10.1 Curasight Details
2.10.2 Curasight Major Business
2.10.3 Curasight Targeted Radionuclide Therapy Product and Solutions
2.10.4 Curasight Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Curasight Recent Developments and Future Plans
2.11 Nordic Nanovector
2.11.1 Nordic Nanovector Details
2.11.2 Nordic Nanovector Major Business
2.11.3 Nordic Nanovector Targeted Radionuclide Therapy Product and Solutions
2.11.4 Nordic Nanovector Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Nordic Nanovector Recent Developments and Future Plans
2.12 Philogen
2.12.1 Philogen Details
2.12.2 Philogen Major Business
2.12.3 Philogen Targeted Radionuclide Therapy Product and Solutions
2.12.4 Philogen Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Philogen Recent Developments and Future Plans
2.13 RadioMedix
2.13.1 RadioMedix Details
2.13.2 RadioMedix Major Business
2.13.3 RadioMedix Targeted Radionuclide Therapy Product and Solutions
2.13.4 RadioMedix Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 RadioMedix Recent Developments and Future Plans
2.14 Telix Pharmaceuticals
2.14.1 Telix Pharmaceuticals Details
2.14.2 Telix Pharmaceuticals Major Business
2.14.3 Telix Pharmaceuticals Targeted Radionuclide Therapy Product and Solutions
2.14.4 Telix Pharmaceuticals Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Telix Pharmaceuticals Recent Developments and Future Plans
2.15 Orano Med
2.15.1 Orano Med Details
2.15.2 Orano Med Major Business
2.15.3 Orano Med Targeted Radionuclide Therapy Product and Solutions
2.15.4 Orano Med Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Orano Med Recent Developments and Future Plans
2.16 Actinium Pharmaceuticals
2.16.1 Actinium Pharmaceuticals Details
2.16.2 Actinium Pharmaceuticals Major Business
2.16.3 Actinium Pharmaceuticals Targeted Radionuclide Therapy Product and Solutions
2.16.4 Actinium Pharmaceuticals Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 Actinium Pharmaceuticals Recent Developments and Future Plans
2.17 Y-mAbs Therapeutics
2.17.1 Y-mAbs Therapeutics Details
2.17.2 Y-mAbs Therapeutics Major Business
2.17.3 Y-mAbs Therapeutics Targeted Radionuclide Therapy Product and Solutions
2.17.4 Y-mAbs Therapeutics Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 Y-mAbs Therapeutics Recent Developments and Future Plans
2.18 Fusion Pharmaceuticals
2.18.1 Fusion Pharmaceuticals Details
2.18.2 Fusion Pharmaceuticals Major Business
2.18.3 Fusion Pharmaceuticals Targeted Radionuclide Therapy Product and Solutions
2.18.4 Fusion Pharmaceuticals Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.18.5 Fusion Pharmaceuticals Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Targeted Radionuclide Therapy Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Targeted Radionuclide Therapy by Company Revenue
3.2.2 Top 3 Targeted Radionuclide Therapy Players Market Share in 2022
3.2.3 Top 6 Targeted Radionuclide Therapy Players Market Share in 2022
3.3 Targeted Radionuclide Therapy Market: Overall Company Footprint Analysis
3.3.1 Targeted Radionuclide Therapy Market: Region Footprint
3.3.2 Targeted Radionuclide Therapy Market: Company Product Type Footprint
3.3.3 Targeted Radionuclide Therapy Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Targeted Radionuclide Therapy Consumption Value and Market Share by Type (2018-2023)
4.2 Global Targeted Radionuclide Therapy Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
5.1 Global Targeted Radionuclide Therapy Consumption Value Market Share by Application (2018-2023)
5.2 Global Targeted Radionuclide Therapy Market Forecast by Application (2024-2029)
6 North America
6.1 North America Targeted Radionuclide Therapy Consumption Value by Type (2018-2029)
6.2 North America Targeted Radionuclide Therapy Consumption Value by Application (2018-2029)
6.3 North America Targeted Radionuclide Therapy Market Size by Country
6.3.1 North America Targeted Radionuclide Therapy Consumption Value by Country (2018-2029)
6.3.2 United States Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
6.3.3 Canada Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
6.3.4 Mexico Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe Targeted Radionuclide Therapy Consumption Value by Type (2018-2029)
7.2 Europe Targeted Radionuclide Therapy Consumption Value by Application (2018-2029)
7.3 Europe Targeted Radionuclide Therapy Market Size by Country
7.3.1 Europe Targeted Radionuclide Therapy Consumption Value by Country (2018-2029)
7.3.2 Germany Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
7.3.3 France Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
7.3.5 Russia Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
7.3.6 Italy Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific Targeted Radionuclide Therapy Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Targeted Radionuclide Therapy Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Targeted Radionuclide Therapy Market Size by Region
8.3.1 Asia-Pacific Targeted Radionuclide Therapy Consumption Value by Region (2018-2029)
8.3.2 China Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
8.3.3 Japan Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
8.3.4 South Korea Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
8.3.5 India Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
8.3.7 Australia Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
9 South America
9.1 South America Targeted Radionuclide Therapy Consumption Value by Type (2018-2029)
9.2 South America Targeted Radionuclide Therapy Consumption Value by Application (2018-2029)
9.3 South America Targeted Radionuclide Therapy Market Size by Country
9.3.1 South America Targeted Radionuclide Therapy Consumption Value by Country (2018-2029)
9.3.2 Brazil Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
9.3.3 Argentina Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa Targeted Radionuclide Therapy Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Targeted Radionuclide Therapy Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Targeted Radionuclide Therapy Market Size by Country
10.3.1 Middle East & Africa Targeted Radionuclide Therapy Consumption Value by Country (2018-2029)
10.3.2 Turkey Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
10.3.4 UAE Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 Targeted Radionuclide Therapy Market Drivers
11.2 Targeted Radionuclide Therapy Market Restraints
11.3 Targeted Radionuclide Therapy Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Targeted Radionuclide Therapy Industry Chain
12.2 Targeted Radionuclide Therapy Upstream Analysis
12.3 Targeted Radionuclide Therapy Midstream Analysis
12.4 Targeted Radionuclide Therapy Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global Targeted Radionuclide Therapy Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Targeted Radionuclide Therapy Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Targeted Radionuclide Therapy Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Targeted Radionuclide Therapy Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Bayer Company Information, Head Office, and Major Competitors
Table 6. Bayer Major Business
Table 7. Bayer Targeted Radionuclide Therapy Product and Solutions
Table 8. Bayer Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Bayer Recent Developments and Future Plans
Table 10. Novartis Company Information, Head Office, and Major Competitors
Table 11. Novartis Major Business
Table 12. Novartis Targeted Radionuclide Therapy Product and Solutions
Table 13. Novartis Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Novartis Recent Developments and Future Plans
Table 15. Lantheus Company Information, Head Office, and Major Competitors
Table 16. Lantheus Major Business
Table 17. Lantheus Targeted Radionuclide Therapy Product and Solutions
Table 18. Lantheus Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Lantheus Recent Developments and Future Plans
Table 20. Aurobindo Pharma Company Information, Head Office, and Major Competitors
Table 21. Aurobindo Pharma Major Business
Table 22. Aurobindo Pharma Targeted Radionuclide Therapy Product and Solutions
Table 23. Aurobindo Pharma Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Aurobindo Pharma Recent Developments and Future Plans
Table 25. Mundipharma Company Information, Head Office, and Major Competitors
Table 26. Mundipharma Major Business
Table 27. Mundipharma Targeted Radionuclide Therapy Product and Solutions
Table 28. Mundipharma Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Mundipharma Recent Developments and Future Plans
Table 30. China Isotope & Radiation Company Information, Head Office, and Major Competitors
Table 31. China Isotope & Radiation Major Business
Table 32. China Isotope & Radiation Targeted Radionuclide Therapy Product and Solutions
Table 33. China Isotope & Radiation Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. China Isotope & Radiation Recent Developments and Future Plans
Table 35. Curium Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 36. Curium Pharmaceuticals Major Business
Table 37. Curium Pharmaceuticals Targeted Radionuclide Therapy Product and Solutions
Table 38. Curium Pharmaceuticals Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Curium Pharmaceuticals Recent Developments and Future Plans
Table 40. Gilead Sciences Company Information, Head Office, and Major Competitors
Table 41. Gilead Sciences Major Business
Table 42. Gilead Sciences Targeted Radionuclide Therapy Product and Solutions
Table 43. Gilead Sciences Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Gilead Sciences Recent Developments and Future Plans
Table 45. Clarity Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 46. Clarity Pharmaceuticals Major Business
Table 47. Clarity Pharmaceuticals Targeted Radionuclide Therapy Product and Solutions
Table 48. Clarity Pharmaceuticals Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Clarity Pharmaceuticals Recent Developments and Future Plans
Table 50. Curasight Company Information, Head Office, and Major Competitors
Table 51. Curasight Major Business
Table 52. Curasight Targeted Radionuclide Therapy Product and Solutions
Table 53. Curasight Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Curasight Recent Developments and Future Plans
Table 55. Nordic Nanovector Company Information, Head Office, and Major Competitors
Table 56. Nordic Nanovector Major Business
Table 57. Nordic Nanovector Targeted Radionuclide Therapy Product and Solutions
Table 58. Nordic Nanovector Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Nordic Nanovector Recent Developments and Future Plans
Table 60. Philogen Company Information, Head Office, and Major Competitors
Table 61. Philogen Major Business
Table 62. Philogen Targeted Radionuclide Therapy Product and Solutions
Table 63. Philogen Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Philogen Recent Developments and Future Plans
Table 65. RadioMedix Company Information, Head Office, and Major Competitors
Table 66. RadioMedix Major Business
Table 67. RadioMedix Targeted Radionuclide Therapy Product and Solutions
Table 68. RadioMedix Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. RadioMedix Recent Developments and Future Plans
Table 70. Telix Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 71. Telix Pharmaceuticals Major Business
Table 72. Telix Pharmaceuticals Targeted Radionuclide Therapy Product and Solutions
Table 73. Telix Pharmaceuticals Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. Telix Pharmaceuticals Recent Developments and Future Plans
Table 75. Orano Med Company Information, Head Office, and Major Competitors
Table 76. Orano Med Major Business
Table 77. Orano Med Targeted Radionuclide Therapy Product and Solutions
Table 78. Orano Med Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. Orano Med Recent Developments and Future Plans
Table 80. Actinium Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 81. Actinium Pharmaceuticals Major Business
Table 82. Actinium Pharmaceuticals Targeted Radionuclide Therapy Product and Solutions
Table 83. Actinium Pharmaceuticals Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 84. Actinium Pharmaceuticals Recent Developments and Future Plans
Table 85. Y-mAbs Therapeutics Company Information, Head Office, and Major Competitors
Table 86. Y-mAbs Therapeutics Major Business
Table 87. Y-mAbs Therapeutics Targeted Radionuclide Therapy Product and Solutions
Table 88. Y-mAbs Therapeutics Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Y-mAbs Therapeutics Recent Developments and Future Plans
Table 90. Fusion Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 91. Fusion Pharmaceuticals Major Business
Table 92. Fusion Pharmaceuticals Targeted Radionuclide Therapy Product and Solutions
Table 93. Fusion Pharmaceuticals Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 94. Fusion Pharmaceuticals Recent Developments and Future Plans
Table 95. Global Targeted Radionuclide Therapy Revenue (USD Million) by Players (2018-2023)
Table 96. Global Targeted Radionuclide Therapy Revenue Share by Players (2018-2023)
Table 97. Breakdown of Targeted Radionuclide Therapy by Company Type (Tier 1, Tier 2, and Tier 3)
Table 98. Market Position of Players in Targeted Radionuclide Therapy, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 99. Head Office of Key Targeted Radionuclide Therapy Players
Table 100. Targeted Radionuclide Therapy Market: Company Product Type Footprint
Table 101. Targeted Radionuclide Therapy Market: Company Product Application Footprint
Table 102. Targeted Radionuclide Therapy New Market Entrants and Barriers to Market Entry
Table 103. Targeted Radionuclide Therapy Mergers, Acquisition, Agreements, and Collaborations
Table 104. Global Targeted Radionuclide Therapy Consumption Value (USD Million) by Type (2018-2023)
Table 105. Global Targeted Radionuclide Therapy Consumption Value Share by Type (2018-2023)
Table 106. Global Targeted Radionuclide Therapy Consumption Value Forecast by Type (2024-2029)
Table 107. Global Targeted Radionuclide Therapy Consumption Value by Application (2018-2023)
Table 108. Global Targeted Radionuclide Therapy Consumption Value Forecast by Application (2024-2029)
Table 109. North America Targeted Radionuclide Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 110. North America Targeted Radionuclide Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 111. North America Targeted Radionuclide Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 112. North America Targeted Radionuclide Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 113. North America Targeted Radionuclide Therapy Consumption Value by Country (2018-2023) & (USD Million)
Table 114. North America Targeted Radionuclide Therapy Consumption Value by Country (2024-2029) & (USD Million)
Table 115. Europe Targeted Radionuclide Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 116. Europe Targeted Radionuclide Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 117. Europe Targeted Radionuclide Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 118. Europe Targeted Radionuclide Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 119. Europe Targeted Radionuclide Therapy Consumption Value by Country (2018-2023) & (USD Million)
Table 120. Europe Targeted Radionuclide Therapy Consumption Value by Country (2024-2029) & (USD Million)
Table 121. Asia-Pacific Targeted Radionuclide Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 122. Asia-Pacific Targeted Radionuclide Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 123. Asia-Pacific Targeted Radionuclide Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 124. Asia-Pacific Targeted Radionuclide Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 125. Asia-Pacific Targeted Radionuclide Therapy Consumption Value by Region (2018-2023) & (USD Million)
Table 126. Asia-Pacific Targeted Radionuclide Therapy Consumption Value by Region (2024-2029) & (USD Million)
Table 127. South America Targeted Radionuclide Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 128. South America Targeted Radionuclide Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 129. South America Targeted Radionuclide Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 130. South America Targeted Radionuclide Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 131. South America Targeted Radionuclide Therapy Consumption Value by Country (2018-2023) & (USD Million)
Table 132. South America Targeted Radionuclide Therapy Consumption Value by Country (2024-2029) & (USD Million)
Table 133. Middle East & Africa Targeted Radionuclide Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 134. Middle East & Africa Targeted Radionuclide Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 135. Middle East & Africa Targeted Radionuclide Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 136. Middle East & Africa Targeted Radionuclide Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 137. Middle East & Africa Targeted Radionuclide Therapy Consumption Value by Country (2018-2023) & (USD Million)
Table 138. Middle East & Africa Targeted Radionuclide Therapy Consumption Value by Country (2024-2029) & (USD Million)
Table 139. Targeted Radionuclide Therapy Raw Material
Table 140. Key Suppliers of Targeted Radionuclide Therapy Raw Materials
List of Figures
Figure 1. Targeted Radionuclide Therapy Picture
Figure 2. Global Targeted Radionuclide Therapy Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Targeted Radionuclide Therapy Consumption Value Market Share by Type in 2022
Figure 4. Beta-emitting
Figure 5. Targeted Alpha Therapy
Figure 6. Global Targeted Radionuclide Therapy Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 7. Targeted Radionuclide Therapy Consumption Value Market Share by Application in 2022
Figure 8. Solid Tumor Picture
Figure 9. Non Hodgkin Lymphoma Picture
Figure 10. Global Targeted Radionuclide Therapy Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 11. Global Targeted Radionuclide Therapy Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 12. Global Market Targeted Radionuclide Therapy Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 13. Global Targeted Radionuclide Therapy Consumption Value Market Share by Region (2018-2029)
Figure 14. Global Targeted Radionuclide Therapy Consumption Value Market Share by Region in 2022
Figure 15. North America Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
Figure 16. Europe Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
Figure 17. Asia-Pacific Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
Figure 18. South America Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
Figure 19. Middle East and Africa Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
Figure 20. Global Targeted Radionuclide Therapy Revenue Share by Players in 2022
Figure 21. Targeted Radionuclide Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 22. Global Top 3 Players Targeted Radionuclide Therapy Market Share in 2022
Figure 23. Global Top 6 Players Targeted Radionuclide Therapy Market Share in 2022
Figure 24. Global Targeted Radionuclide Therapy Consumption Value Share by Type (2018-2023)
Figure 25. Global Targeted Radionuclide Therapy Market Share Forecast by Type (2024-2029)
Figure 26. Global Targeted Radionuclide Therapy Consumption Value Share by Application (2018-2023)
Figure 27. Global Targeted Radionuclide Therapy Market Share Forecast by Application (2024-2029)
Figure 28. North America Targeted Radionuclide Therapy Consumption Value Market Share by Type (2018-2029)
Figure 29. North America Targeted Radionuclide Therapy Consumption Value Market Share by Application (2018-2029)
Figure 30. North America Targeted Radionuclide Therapy Consumption Value Market Share by Country (2018-2029)
Figure 31. United States Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
Figure 32. Canada Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
Figure 33. Mexico Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
Figure 34. Europe Targeted Radionuclide Therapy Consumption Value Market Share by Type (2018-2029)
Figure 35. Europe Targeted Radionuclide Therapy Consumption Value Market Share by Application (2018-2029)
Figure 36. Europe Targeted Radionuclide Therapy Consumption Value Market Share by Country (2018-2029)
Figure 37. Germany Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
Figure 38. France Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
Figure 39. United Kingdom Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
Figure 40. Russia Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
Figure 41. Italy Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
Figure 42. Asia-Pacific Targeted Radionuclide Therapy Consumption Value Market Share by Type (2018-2029)
Figure 43. Asia-Pacific Targeted Radionuclide Therapy Consumption Value Market Share by Application (2018-2029)
Figure 44. Asia-Pacific Targeted Radionuclide Therapy Consumption Value Market Share by Region (2018-2029)
Figure 45. China Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
Figure 46. Japan Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
Figure 47. South Korea Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
Figure 48. India Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
Figure 49. Southeast Asia Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
Figure 50. Australia Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
Figure 51. South America Targeted Radionuclide Therapy Consumption Value Market Share by Type (2018-2029)
Figure 52. South America Targeted Radionuclide Therapy Consumption Value Market Share by Application (2018-2029)
Figure 53. South America Targeted Radionuclide Therapy Consumption Value Market Share by Country (2018-2029)
Figure 54. Brazil Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
Figure 55. Argentina Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
Figure 56. Middle East and Africa Targeted Radionuclide Therapy Consumption Value Market Share by Type (2018-2029)
Figure 57. Middle East and Africa Targeted Radionuclide Therapy Consumption Value Market Share by Application (2018-2029)
Figure 58. Middle East and Africa Targeted Radionuclide Therapy Consumption Value Market Share by Country (2018-2029)
Figure 59. Turkey Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
Figure 60. Saudi Arabia Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
Figure 61. UAE Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
Figure 62. Targeted Radionuclide Therapy Market Drivers
Figure 63. Targeted Radionuclide Therapy Market Restraints
Figure 64. Targeted Radionuclide Therapy Market Trends
Figure 65. Porters Five Forces Analysis
Figure 66. Manufacturing Cost Structure Analysis of Targeted Radionuclide Therapy in 2022
Figure 67. Manufacturing Process Analysis of Targeted Radionuclide Therapy
Figure 68. Targeted Radionuclide Therapy Industrial Chain
Figure 69. Methodology
Figure 70. Research Process and Data Source
